Tag Archives: John Carroll

Patients lose, lawyers win, as AbbVie does deal with Amgen to delay Humira biosim.

The News: Amgen Inc. (Thousand Oaks CA) has agreed to delay the US launch of its FDA-approved biosimilar version of AbbVie Inc.’s (North Chicago) Humira (adalimumab) until 2023, under a… Read more »

Zai Lab’s U.S. IPO marks another white-hot Chinese offering that begs the question: why are these Asian offerings so special?

The News: Shang­hai-based biotech Zai Lab Ltd. raised $150 mil­lion from its up­sized IPO last Wednes­day (September 20, 2017), sell­ing 8.3 mil­lion shares at $18 each. After trad­ing began, the… Read more »

Novartis CEO Jimenez is stepping down; does successor Narasimhan have the right stuff to take the reins in 2018?

The News: Swiss pharmaceuticals titan Novartis AG (Basel) will get a new chief executive in 2018–Dr. Vasant Narasimhan (pdf)–after Joseph Jimenez proclaimed his upcoming retirement effective in February. Jimenez has… Read more »

Merck’s Frazier leads the way quitting Trump business council after Charlottesville; J&J’s Gorsky’s bail way too late.

The News: One day after J&J chief exec Alex Gorsky pub­licly com­mit­ted to stay­ing on Pres­i­dent Don­ald Trump’s man­u­fac­tur­ing coun­cil, he abruptly re­versed course–just as the sud­den mass departure of ex­ec­u­tives forced… Read more »

Zynerba sinks twice as cannabis trials flop; strike three looms, so where’s the Ouija board?

The News: Zynerba Pharmaceuticals Inc. (ZYNE) lost more than half its value last week to $7.03 after the drug developer said its synthetic cannabis-based gel for epilepsy failed a mid-stage… Read more »

Kite submits IND for CAR-T multiple myeloma treatment; Novartis keeping wary eye on rival’s latest move in high-stakes race.

The News: Kite Pharma Inc. (Santa Monica CA) said it has submitted to the FDA an Investigational New Drug (IND) application to launch a Phase 1, first-in-human trial of a… Read more »

Public craves coverage of Shkreli’s trial for securities fraud; have we lost our senses entirely?

The News: Martin Shkreli is on trial in Federal District Court in Brooklyn, accused of eight counts of securities and wire fraud from his time running two hedge funds and… Read more »

Merck’s Keytruda aces another cancer trial as results dazzle researchers

The News: Hot on the heels of the final presentation at ASCO’s 4-day conference in Chicago, a small, new study is causing jaws to drop after it found that a… Read more »

What’s wrong with Novartis? Actually nothing.

The News: Novartis AG (Basel CHE) has been the subject of widespread and lingering chatter to the effect that its stature among the Big Pharma league players has diminished, and… Read more »

Novartis 1Q results remain insomnia cure; investors plead for something, anything to get excited about

The News: Novartis AG shares moved higher Tuesday (April 25, 2017) after the pharmaceuticals group clung to full-year earnings targets and barely beat analysts’ estimates for first-quarter earnings. The Swiss… Read more »